Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

Exclusion criteria

• ✕. Patients who, during the core study, developed any psychiatric condition that requires treatment with medication or that may interfere with study participation and /or study assessments.
• ✕. Patients who during the core study developed cardiovascular disorders.
• ✕. Pregnant women.
• ✕. Patients who developed seizures during the core study.
• ✕. Diagnosis of glaucoma, hyperthyroidism, pheochromocytoma.
• ✕. Diagnosis or family history of Tourette's syndrome.
• ✕. Patients who during the core study developed cerebrovascular disorders such as cerebral aneurysm, vascular abnormalities including vasculitis and stroke